公开(公告)号：US20250049881A1

公开(公告)日：2025-02-13

申请号：US18602930

申请日：2024-03-12

Applicant: Bausch Health Ireland Limited

Inventor： Stephen Comiskey ,  Rong Feng ,  John Foss ,  Kunwar Shailubhai

IPC: A61K38/10 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/192 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/765 ,  A61K31/78 ,  A61K38/12 ,  A61K45/06 ,  A61K47/12 ,  A61K47/38 ,  C07K7/08 ,  C07K7/54 ,  C07K7/64

Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

公开(公告)号：US12076404B2

公开(公告)日：2024-09-03

申请号：US17119780

申请日：2020-12-11

Applicant: BAUSCH HEALTH IRELAND LIMITED

Inventor： Varsha Bhatt ,  Nayan Desai ,  Radhakrishnan Pillai

IPC: A61K31/454 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K47/10 ,  A61K47/18 ,  A61K47/12

CPC classification number: A61K47/183 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/08 ,  A61K31/454 ,  A61K47/10 ,  A61K47/12

Abstract: The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.

公开(公告)号：US20240287137A1

公开(公告)日：2024-08-29

申请号：US18511852

申请日：2023-11-16

Applicant: Bausch Health Ireland Limited

Inventor： KUNWAR SHAILUBHAI ,  Stephen Comiskey ,  Rong Feng ,  Juncai Bai ,  Ruoping Zhang ,  Jun Jia ,  Junfeng Zhou ,  Qiao Zhao ,  Guoqing Zhang

IPC: C07K7/08 ,  A61K38/10 ,  B01D15/42 ,  C07K1/14 ,  C12N9/88

CPC classification number: C07K7/08 ,  A61K38/10 ,  B01D15/424 ,  C07K1/14 ,  C12N9/88 ,  C12Y406/01002

Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

公开(公告)号：US20240261314A1

公开(公告)日：2024-08-08

申请号：US18639630

申请日：2024-04-18

Applicant: BAUSCH HEALTH IRELAND LIMITED

Inventor： Varsha BHATT ,  Radhakrishnan PILLAI ,  Arturo ANGEL

IPC: A61K31/7056 ,  A61K8/22 ,  A61K8/34 ,  A61K8/49 ,  A61K8/73 ,  A61K9/00 ,  A61K9/06 ,  A61K31/192 ,  A61K31/327 ,  A61K47/02 ,  A61K47/10 ,  A61K47/32 ,  A61P17/10 ,  A61Q19/00

CPC classification number: A61K31/7056 ,  A61K8/22 ,  A61K8/345 ,  A61K8/4913 ,  A61K8/731 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/192 ,  A61K31/327 ,  A61K47/02 ,  A61K47/10 ,  A61K47/32 ,  A61P17/10 ,  A61Q19/005

Abstract: The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.

公开(公告)号：US11957753B2

公开(公告)日：2024-04-16

申请号：US15966367

申请日：2018-04-30

Applicant: BAUSCH HEALTH IRELAND LIMITED

Inventor： Arturo Angel ,  Gordon Dow

IPC: A61K47/14 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K9/127 ,  A61K9/14 ,  A61K31/573 ,  A61K31/58 ,  A61P17/06

CPC classification number: A61K47/14 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K9/127 ,  A61K31/573 ,  A61K31/58 ,  A61P17/06

Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

公开(公告)号：US20230190936A1

公开(公告)日：2023-06-22

申请号：US18167809

申请日：2023-02-10

Applicant: BAUSCH HEALTH IRELAND LIMITED

Inventor： Arturo ANGEL ,  Gordon DOW

IPC: A61K47/14 ,  A61K31/58 ,  A61K31/573 ,  A61K9/06 ,  A61K9/00 ,  A61K9/107 ,  A61K9/127 ,  A61P17/06

CPC classification number: A61K47/14 ,  A61K9/06 ,  A61K9/0014 ,  A61K9/107 ,  A61K9/127 ,  A61K31/58 ,  A61K31/573 ,  A61P17/06

Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

公开(公告)号：US11648256B2

公开(公告)日：2023-05-16

申请号：US17993817

申请日：2022-11-23

Applicant: Bausch Health Ireland Limited

Inventor： Gordon J. Dow ,  Radhakrishnan Pillai ,  Varsha D. Bhatt

IPC: A61K31/573 ,  A61K9/00 ,  A61K45/06 ,  A61K9/06 ,  A61K31/192 ,  A61K47/26 ,  A61K9/12 ,  A61K47/14 ,  A61K47/44 ,  A61K9/107 ,  A61K31/4436

CPC classification number: A61K31/573 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K9/12 ,  A61K31/192 ,  A61K31/4436 ,  A61K45/06 ,  A61K47/14 ,  A61K47/26 ,  A61K47/44 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/192 ,  A61K2300/00 ,  A61K31/4436 ,  A61K2300/00

Abstract: Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.

公开(公告)号：US20230116647A1

公开(公告)日：2023-04-13

申请号：US17913843

申请日：2021-03-24

Applicant: Bausch Health Ireland Limited

Inventor： Maxime Barakat ,  Howard Franklin ,  Zeev Heimanson ,  Thejasvi Ramakrishna ,  Jason Lamar Vittitow

IPC: A61K31/437 ,  A61K45/06 ,  A61K31/4706

Abstract: Provided herein are methods for treating COVID-19 or associated GI symptoms with rifaximin compositions.

公开(公告)号：US20230047106A1

公开(公告)日：2023-02-16

申请号：US17969638

申请日：2022-10-19

Applicant: Bausch Health Ireland Limited

Inventor： Yunik Chang ,  Gordon J. Dow ,  Radhakrishnan Pillai

IPC: A61K31/7056 ,  A61K31/075 ,  A61K47/10 ,  A61K8/02 ,  A61K8/04 ,  A61K8/34 ,  A61K8/55 ,  A61K8/38 ,  A61K45/06 ,  A61Q19/00 ,  A61K9/00 ,  A61K31/327 ,  A61K31/235 ,  A61K9/14 ,  A61K47/32

Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.

公开(公告)号：US20220380449A1

公开(公告)日：2022-12-01

申请号：US17642130

申请日：2020-09-11

Applicant: BAUSCH HEALTH IRELAND LIMITED

Inventor： Robert J. Israel

IPC: C07K16/24 ,  A61P1/16

Abstract: The present disclosure is directed to a method of treating nonalcoholic fatty liver disease (NAFLD), and subsets thereof such as nonalcoholic steatohepatitis (NASH), using an IL-17 antagonist, such as a monoclonal antibody that specifically binds to IL-17 receptor A (IL-17RA).